How will Medical Devices be regulated following the end of the Brexit Transition Period

This whitepaper summarises the key elements of MHRA’s guidance document on medical devices, regarding registration, assessment procedures, labeling, post-market surveillance, and vigilance that will apply for devices placed on the market in Great Britain (England, Wales, and Scotland) and Northern Ireland. This document provides a list of actions that manufacturers of medical devices should take in order to continue the placement of their products on the EU and UK markets.

Posted:

Download

Together Beyond COVID-19: Key trends that have been accelerated by the pandemic

Coronavirus has shattered our world and changed nearly all aspects of our lives. It has also changed our relationship with healthcare. It is slowly becoming a cliché to say that COVID-19 has catalyzed life sciences and healthcare trends – but nevertheless, it’s true. Industry leaders and PharmaLex experts recently discussed the key trends being accelerated since the start of the COVID-19 pandemic. This paper summarizes the main points of their discussions as well as the possible implications of these trends.

Posted:

Download

Brexit Considerations for Industry: The current Position

The UK formally left the EU on 31st January 2020 and the transition period, as set out in the withdrawal agreement, will come to an end on 31st December 2020. During this transition period the UK has continued to remain under EU pharmaceutical law. Our PharmaLex.perts have created an interesting Whitepaper, which introduces you to important current considerations about Brexit for the industry.

Posted:

Download

Together Beyond COVID-19 - A Look at the Future

In cooperation with EY, open-ended interviews were conducted with top pharmaceutical companies around Europe to understand the challenges that the pharmaceutical industry faces during COVID-19. This paper summarizes the main highlights, together with the future vision.

Posted:

Download

The Medical Device Regulation – Readiness for May 2021

This paper highlights what medical device manufacturers and other Economic Operators must be aware of ahead of the revised May 2021 deadline.

Posted:

Download

Analysis of EMA's Product Management Services

This paper gives details on the background and recommended steps about the Analysis of EMA’s Product Management Services, the current Implementation Guide and future Development.

Posted:

Download

The Challenges of Achieving and Maintaining CMC Compliance

This paper highlights just a few key points that need consideration ahead of achieving and maintaining CMC Compliance in a more sustainable way.

Posted:

Download

Nitrosamines - information for MAHs

This paper gives details on the background and recommended steps required to ensure your medicinal products comply with the latest guidance for nitrosamines.

Posted:

Download

Software, AI and Medical Devices - What's Up?

This paper highlights just a few key points that need consideration ahead of the new Medical Device Regulation 2017/745 (MDR) being implemented in 26th May 2020.

Posted:

Download

Pre-IND meetings | The opportunity for early FDA feedback

This first meeting establishes the tone of your Agency relationship, and as one of the desired outcomes, you want the Agency to gain respect for your company and your science.

Posted:

Download

Differing CMC requirements: US and EU

Different CMC regulatory requirements in various regions impose obstacles when considering expansion into other markets.

Posted:

Download

Five secrets of great publishers

The FDA’s mandate for life science companies and manufacturers to submit information in electronic
format has solidified the Regulatory Publisher’s function as being essential to the drug development
process.

Posted:

Download

Manage effectively your Merger and Acquisition activities

Companies engaging in Merger and Acquisition (M&A) activities aim to gain momentum by undertaking one or a combination of the following to: Level of Regulatory Affairs Involvement with M&A Programs, Increase market share by consolidating their product portfolio into specific therapeutic areas, Replenish their previously dwindling product pipeline, Enter into emerging markets with existing and new products, Reduce costs through the consolidation of manufacturing sites.

Posted:

Download